Romidepsin-CHOEP Followed by High-Dose Chemotherapy and Stem-Cell Transplantation in Untreated Peripheral T-Cell Lymphoma: Results of the PTCL13 Phase Ib/II Study

On these premises, we designed a phase Ib/II trial (PTCL13) in young patients with newly diagnosed PTCL to define the maximum tolerated dose (MTD) and to evaluate the safety, tolerability and efficacy of romidepsin in addition to CHOEP, in a program containing a final consolidation with SCT. Here, we report the final analysis of the phase Ib and the phase II part of PTCL13 trial.